PF 5230907

Drug Profile

PF 5230907

Alternative Names: Factor Xa variant (IL16); FXa; FXaI16L; PF 907; PF-05230907; PF-5230907

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cerebral haemorrhage

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cerebral-haemorrhage(In volunteers) in Belgium (IV, Infusion)
  • 26 Oct 2017 Pfizer terminates a phase I trial for strategic reasons in Cerebral haemorrhage in United Kingdom, Spain, Canada, USA (IV, Injection) (NCT02687191)
  • 03 Dec 2016 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Cerebral haemorrhage (In volunteers) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top